PMID- 18839033
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151105
LR  - 20200414
IS  - 1110-0362 (Print)
IS  - 1110-0362 (Linking)
VI  - 19
IP  - 1
DP  - 2007 Mar
TI  - Limited Field Radiotherapy Concomitant with Cisplatin/Etoposide Followed by 
      Consolidation Docetaxel for the Treatment of Inoperable Stage III Non-Small Cell 
      Lung Cancer.
PG  - 28-38
AB  - PURPOSE: To evaluate the efficacy and outcome of concomitant cisplatin/etoposide 
      and limited field irradiation followed by consolidation docetaxel in patients 
      with locally advanced non small cell lung cancer (NSCLC). PATIENTS AND METHODS: 
      This is a prospective phase II study that included 32 patients with locally 
      advanced stage III NSCLC who presented to the Radiation Oncology and Chest 
      Departments- Ain Shams University hospitals, and Sohag Cancer Center between May 
      2004 and August 2006. Eligible patients were treated first with two cycles of 
      cisplatin 50mg/m2/day on days 1, 8, 29 and 36 and etoposide 50mg/m2/day on days 
      1-5 and 29-33 concomitant with conventionally fractionated radiation (66Gy in 2Gy 
      fractions) to the gross primary disease and regionally involved lymph nodes 
      followed by 3 cycles of consolidation single agent docetaxel, 75mg/m2/3 weeks. 
      RESULTS: The median follow-up duration was 13.5 months (range from 6 to 30 
      months). The median survival was 17.4 months and the median progression free 
      survival was 13 months. A total of 20 patients (62.5%) had treatment failure, 47% 
      had an in field failure, 44% had distant failure, and one patient (3%) had 
      isolated nodal failure (INF). Neutropenia (15.5%), anemia (19%), nausea and 
      vomiting (15.5), esophagitis (9%) and pneumonitis (3%) were the most severe, 
      grade 3 and 4, acute toxicities recorded during concomitant chemoradiation and 3 
      patients (9%) had grade 3 late esophagitis. Neutropenia (35%) and anemia (17%) 
      were the most pronounced, grade 3 and 4, toxicities during consolidation 
      chemotherapy. CONCLUSION: Concomitant chemoradiation, without elective nodal 
      irradiation (ENI), is a promising approach for management of locally advanced 
      NSCLC. Conformal irradiation with possible dose escalation may provide an 
      opportunity for more improvement of the therapeutic ratio. The addition of 
      consolidation docetaxel is still questionable and needs more investigation. Key 
      Words: NSCLC , Radiation , Cisplatin , Etoposide , Docetaxel.
FAU - Mostafa, Ehab
AU  - Mostafa E
AD  - The Departments of Radiation Oncology&Nuclear Medicine, Ain Shams University.
FAU - Khatab, Adel
AU  - Khatab A
FAU - Al-Adwy, Eman R
AU  - Al-Adwy ER
FAU - Al-Assal, Gihan M
AU  - Al-Assal GM
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Egypt Natl Canc Inst
JT  - Journal of the Egyptian National Cancer Institute
JID - 9424566
EDAT- 2008/10/08 09:00
MHDA- 2008/10/08 09:01
CRDT- 2008/10/08 09:00
PHST- 2008/10/08 09:00 [pubmed]
PHST- 2008/10/08 09:01 [medline]
PHST- 2008/10/08 09:00 [entrez]
PST - ppublish
SO  - J Egypt Natl Canc Inst. 2007 Mar;19(1):28-38.